Biotherapies in Clinical Trials With Mammastatin at Houston's M.D. Anderson Cancer Center for Treatment of Breast Cancer Patients.ANN ARBOR Ann Arbor, city (1990 pop. 109,592), seat of Washtenaw co., S Mich., on the Huron River; inc. 1851. It is a research and educational center, with a large number of government and industrial research and development firms, many in high-technology fields such as , Mich.--(BW HealthWire)--Nov. 10, 1999-- Biotherapies Inc., a four-year-old biotechnology firm that is developing the protein Mammastatin for use in treating advanced-stage breast cancer patients, announced that it is in Phase I/II clinical trials with a series of patients at the M.D. Anderson Anderson, river, Canada Anderson, river, c.465 mi (750 km) long, rising in several lakes in N central Northwest Territories, Canada. It meanders north and west before receiving the Carnwath River and flowing north to Liverpool Bay, an arm of the Arctic Cancer Center in Houston, Texas “Houston” redirects here. For other uses, see Houston (disambiguation). Houston (pronounced /'hjuːstən/) is the largest city in the state of Texas and the . Approval to conduct the trials was given by the Federal Food and Drug Administration and began in July under the direction of Dr. Francisco Esteva at M.D. Anderson, one of the nation's leading cancer research and treatment facilities. The trial has been primarily designed to test for safety and determine the maximum tolerated dose of the Mammastatin therapy. In addition, the trial is designed to provide preliminary efficacy data that will be used to assist in the design of further Phase II and/or Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA trials. Thirty-six late-stage breast cancer patients will participate in groups of six at different dosages levels. Enrollment for the later groups is being completed and the trial will continue for six months once enrollment is finished. Biotherapies has been developing the protein since the inception of the company in 1995. The firm is funded privately and has raised some $5 million to date for its work. About Biotherapies Biotherapies is dedicated to the development of better cancer therapies and diagnostics (1) Software routines that test hardware components (memory, keyboard, disks, etc.). Diagnostics are often stored in ROM chips and activated on startup. (2) Error messages in a programmer's source code that refer to statements or syntax that the compiler or assembler . Its lead product, Mammastatin, is a protein to control abnormal cell growth in breast tissue. The firm was founded by Dr. Paul Ervin Jr. who earlier worked on the development of Mammastatin while a research scientist for eight years at the University of Michigan (body, education) University of Michigan - A large cosmopolitan university in the Midwest USA. Over 50000 students are enrolled at the University of Michigan's three campuses. The students come from 50 states and over 100 foreign countries. Cancer Center. Biotherapies licensed the technology for Mammastatin from the University of Michigan. Dr. Ervin and scientific Director and Chairman of the Board Tom Trimmer trimmer see resco nail trimmer, toenail scissors. , a veteran medical technology company executive, is President and directs the financial investment, marketing and administrative operations. The firm's headquarters and research laboratory are in the Biotechnology Development Center, 5692 Plymouth Road, Ann Arbor, MI 48105. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion